EUVIMEDEUVIMED entdecken
Crossref

Australian Gonococcal Surveillance Programme Annual Report, 2023

Monica M Lahra, Sebastiaan van Hal, Tiffany R Hogan

Communicable Diseases Intelligence · 2025

DOI: 10.33321/cdi.2025.49.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Monica M Lahra und 2 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pat…. Hauptthemen laut MEDLINE: Gonorrhea, Neisseria gonorrhoeae, Anti-Bacterial Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae for more than 40 years. In 2023, a total of 10,105 isolates from patients in the public and private sectors, in all jurisdictions, were tested for in vitro antimicrobial susceptibility by standardised methods. Nationally, in 2023, the AGSP captured antimicrobial susceptibility data for 25% of all gonococcal infection notifications. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2023, of N. gonorrhoeae isolates tested, 0.22% (22/10,105) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration (MIC) value ≥ 0.125 mg/L. Resistance to azithromycin was reported in 4.5% of N. gonorrhoeae isolates, proportionally stable since 2019. There were 27 isolates (0.27%) with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Victoria (13), New South Wales (11), non-remote Western Australia (2) and Queensland (1). This is the highest number ever detected and reported in a twelve-month period by the AGSP. In 2023, penicillin resistance was found in 30.7% of gonococcal isolates, and ciprofloxacin resistance in 60.3%, although there was considerable variation by jurisdiction. In some remote settings, penicillin remains recommended as part of an empiric therapy strategy. However, in 2023, in remote Northern Territory, five penicillin-resistant isolates were reported; and in remote Western Australia, 14.1% of gonococcal isolates (10/71) were penicillin resistant. In addition, there were eight ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates have increased in remote Western Australia (16/71; 22.5%). This increase in penicillin-resistant Neisseria gonorrhoeae in the Northern Territory has effected a change in gonococcal treatment recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GonorrheaNeisseria gonorrhoeaeAnti-Bacterial AgentsHumansAustraliaMicrobial Sensitivity TestsAzithromycinDrug Resistance, BacterialFemaleCeftriaxoneMaleAdultEpidemiological MonitoringAnnual Reports as TopicPopulation Surveillance

Stichwörter der Autor:innen

Neisseria gonorrhoeaeantimicrobial resistancedisease surveillancegonococcal infection

Substanzen

Anti-Bacterial AgentsAzithromycinCeftriaxone

Autor:innen und Institutionen

  • World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia.
  • School of Medical Sciences, Faculty of Medicine, The University of New South Wales, NSW, 2052 Australia.
  • New South Wales Health Pathology, Microbiology, Royal Prince Alfred Hospital Camperdown, NSW, Australia.
  • School of Medicine, University of Sydney.

Zitieren

APA

Lahra, M. M., van Hal, S., & Hogan, T. R. (2025). Australian Gonococcal Surveillance Programme Annual Report, 2023. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.007

Vancouver

Lahra MM, van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2023. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.007

BibTeX
@article{Lahra2025,
  author = {Lahra, Monica M and van Hal, Sebastiaan and Hogan, Tiffany R},
  title = {Australian Gonococcal Surveillance Programme Annual Report, 2023},
  journal = {Communicable Diseases Intelligence},
  year = {2025},
  doi = {10.33321/cdi.2025.49.007}
}
Kostenlos starten →